Global API Market Outlook 2020
The global API market has been garnering a lot of attention since the last few years. In our report “Global API Market Outlook 2020”, the growth of the global API market has been forecasted by looking at the current market trends. This market is expected to grow at a CAGR of 6.5% from 2014-2020. The market has been segmented by type of manufacturing, type of drug, type of API and by therapeutic segment; and each segment’s market has also been forecasted.
The market has been divided into four major geographies which comprise of North America, Asia Pacific, Europe and the Rest of the World. For every region, the current and future outlook of the API sector has been provided. A future opportunity assessment of every region has also been done to help highlight the areas with promising possibilities.
Excellent growth has been witnessed in pharmaceutical industry in emerging markets. Rising affordability, enhanced life expectancy and improved standard of living are all providing impetus to the demand of pharmaceuticals. However, major regulatory changes in the United States and Europe are set to change the API landscape. As patterns in developed regions continue to remain flat and opportunities for growth shift from traditional markets, the API industry is expected to witness the rise of second wave emerging markets, such as India and China.
As the days of the blockbuster drugs start waning, more flexible manufacturing focused on personalized medicine can be seen as the future of the pharmaceutical business. The report elaborates on the rise of more such trends and challenges, and their possible impacts on the industry.
We have also covered the key players in the Merchant API Market. For every player, a brief business overview, geographical revenue break up, and segment-wise revenue break up has been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global API market.
The market has been divided into four major geographies which comprise of North America, Asia Pacific, Europe and the Rest of the World. For every region, the current and future outlook of the API sector has been provided. A future opportunity assessment of every region has also been done to help highlight the areas with promising possibilities.
Excellent growth has been witnessed in pharmaceutical industry in emerging markets. Rising affordability, enhanced life expectancy and improved standard of living are all providing impetus to the demand of pharmaceuticals. However, major regulatory changes in the United States and Europe are set to change the API landscape. As patterns in developed regions continue to remain flat and opportunities for growth shift from traditional markets, the API industry is expected to witness the rise of second wave emerging markets, such as India and China.
As the days of the blockbuster drugs start waning, more flexible manufacturing focused on personalized medicine can be seen as the future of the pharmaceutical business. The report elaborates on the rise of more such trends and challenges, and their possible impacts on the industry.
We have also covered the key players in the Merchant API Market. For every player, a brief business overview, geographical revenue break up, and segment-wise revenue break up has been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global API market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. APIS - AN INTRODUCTION
4. GLOBAL API INDUSTRY
5. DRIVERS & CHALLENGES
5.1 Drivers
5.1.1 Rise in Geriatric Population
5.1.2 Increasing Prevalence of Chronic Diseases
5.1.3 Patent Expiry Opening Market for Generic APIs
5.1.4 Asian Markets Offer Considerable Growth Potential
5.2 Challenges
5.2.1 Surging Prices Holding Back Branded Drug Market
5.2.2 Increasingly Challenging Regulatory Environment
5.2.3 Lengthy Product Approval Process
5.2.4 Lack of Transparency in Supply Chain
6. MARKET SEGMENTATION
6.1 By Type of Manufacturing
6.1.1 Captive Market
6.1.2 Merchant Market
6.2 By Type of Drug
6.2.1 Generic Drug API
6.2.2 Branded Drug API
6.3 By Type of API
6.3.1 Chemical/Small Molecule API
6.3.2 Biotech API
6.4 By Key Geographical Markets
6.4.1 North America
6.4.2 Asia-Pacific
6.4.3 Europe
6.4.4 Rest of the World
6.5 By Therapeutic Segments
6.5.1 Cardiovascular Diseases
6.5.2 Diabetes
6.5.3 Central Nervous System Disorders
6.5.4 Oncology
6.5.5 Others
7. TRENDS AND DEVELOPMENTS
7.1 Nanocrystals of APIs to Improve Solubility
7.2 Technological Advancements Aiding API Production
8. COMPETITIVE LANDSCAPE
8.1 BASF SE
8.2 Kyowa Hakko Kirin
8.3 Teva Active Pharmaceuticals Ingredients
8.4 Lonza
8.5 Dr. Reddy’s Laboratories
8.6 Aurobindo Pharma Limited
8.7 Pfizer
8.8 Divis Laboratories Limited
8.9 Royal DSM
8.10 Boehringer Ingelheim GmbH
2. RESEARCH METHODOLOGY
3. APIS - AN INTRODUCTION
4. GLOBAL API INDUSTRY
5. DRIVERS & CHALLENGES
5.1 Drivers
5.1.1 Rise in Geriatric Population
5.1.2 Increasing Prevalence of Chronic Diseases
5.1.3 Patent Expiry Opening Market for Generic APIs
5.1.4 Asian Markets Offer Considerable Growth Potential
5.2 Challenges
5.2.1 Surging Prices Holding Back Branded Drug Market
5.2.2 Increasingly Challenging Regulatory Environment
5.2.3 Lengthy Product Approval Process
5.2.4 Lack of Transparency in Supply Chain
6. MARKET SEGMENTATION
6.1 By Type of Manufacturing
6.1.1 Captive Market
6.1.2 Merchant Market
6.2 By Type of Drug
6.2.1 Generic Drug API
6.2.2 Branded Drug API
6.3 By Type of API
6.3.1 Chemical/Small Molecule API
6.3.2 Biotech API
6.4 By Key Geographical Markets
6.4.1 North America
6.4.2 Asia-Pacific
6.4.3 Europe
6.4.4 Rest of the World
6.5 By Therapeutic Segments
6.5.1 Cardiovascular Diseases
6.5.2 Diabetes
6.5.3 Central Nervous System Disorders
6.5.4 Oncology
6.5.5 Others
7. TRENDS AND DEVELOPMENTS
7.1 Nanocrystals of APIs to Improve Solubility
7.2 Technological Advancements Aiding API Production
8. COMPETITIVE LANDSCAPE
8.1 BASF SE
8.2 Kyowa Hakko Kirin
8.3 Teva Active Pharmaceuticals Ingredients
8.4 Lonza
8.5 Dr. Reddy’s Laboratories
8.6 Aurobindo Pharma Limited
8.7 Pfizer
8.8 Divis Laboratories Limited
8.9 Royal DSM
8.10 Boehringer Ingelheim GmbH
LIST OF FIGURES:
Figure 4-1: Global - API Market (Billion US$), 2014-2020
Figure 5-1: Worldwide Population above 60 Years (Billion), 2014 & 2050
Figure 5-2: US - Population Suffering from Chronic Condition (Million), 2014 & 2020
Figure 6-1: Global - Share of Captive and Merchant Market in API Market (2014)
Figure 6-2: Global - API Captive Market (Billion US$), 2014-2020
Figure 6-3: Global - API Merchant Market (Billion US$), 2014-2020
Figure 6-4: Global - Share of Branded and Generic Market in API Market (2014)
Figure 6-5: Global - Generic API Market (Billion US$), 2014-2020
Figure 6-6: Global - Branded API Market (Billion US$), 2014-2020
Figure 6-7: Global - Share of Synthetic and Biotech APIs in API Market (2014)
Figure 6-8: Global - Chemical/Small Molecule API Market (Billion US$), 2014-2020
Figure 6-9: Global - Biotech API Market (Billion US$), 2014-2020
Figure 6-10: North America - API Market (Billion US$), 2014-2020
Figure 6-11: Asia-Pacific - API Market (US$ Billion), 2014-2020
Figure 6-12: Europe - API Market (Billion US$), 2014-2020
Figure 6-13: ROW - API Market (Billion US$), 2014-2020
Figure 6-14: Breakup of Global API Market by Therapeutic Segments (%), 2014
Figure 8-1: BASF SE - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-2: Kyowa Hakko Kirin - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-3: Teva Pharmaceutical Industries Limited - Break up of Revenue by Geographical Segment (%), 2014
Figure 8-4: Lonza - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-5: Dr. Reddy's Laboratories - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-6: Aurobindo Pharma Limited - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-7: Pfizer - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-8: Divis Laboratories Limited - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-9: Royal DSM - Break up of Revenue by Geographic Origin (%), 2014
Figure 8-10: Boehringer Ingelheim GmbH - Break up of Revenue by Geographic Segment (%), 2014
Figure 4-1: Global - API Market (Billion US$), 2014-2020
Figure 5-1: Worldwide Population above 60 Years (Billion), 2014 & 2050
Figure 5-2: US - Population Suffering from Chronic Condition (Million), 2014 & 2020
Figure 6-1: Global - Share of Captive and Merchant Market in API Market (2014)
Figure 6-2: Global - API Captive Market (Billion US$), 2014-2020
Figure 6-3: Global - API Merchant Market (Billion US$), 2014-2020
Figure 6-4: Global - Share of Branded and Generic Market in API Market (2014)
Figure 6-5: Global - Generic API Market (Billion US$), 2014-2020
Figure 6-6: Global - Branded API Market (Billion US$), 2014-2020
Figure 6-7: Global - Share of Synthetic and Biotech APIs in API Market (2014)
Figure 6-8: Global - Chemical/Small Molecule API Market (Billion US$), 2014-2020
Figure 6-9: Global - Biotech API Market (Billion US$), 2014-2020
Figure 6-10: North America - API Market (Billion US$), 2014-2020
Figure 6-11: Asia-Pacific - API Market (US$ Billion), 2014-2020
Figure 6-12: Europe - API Market (Billion US$), 2014-2020
Figure 6-13: ROW - API Market (Billion US$), 2014-2020
Figure 6-14: Breakup of Global API Market by Therapeutic Segments (%), 2014
Figure 8-1: BASF SE - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-2: Kyowa Hakko Kirin - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-3: Teva Pharmaceutical Industries Limited - Break up of Revenue by Geographical Segment (%), 2014
Figure 8-4: Lonza - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-5: Dr. Reddy's Laboratories - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-6: Aurobindo Pharma Limited - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-7: Pfizer - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-8: Divis Laboratories Limited - Break up of Revenue by Geographic Segment (%), 2014
Figure 8-9: Royal DSM - Break up of Revenue by Geographic Origin (%), 2014
Figure 8-10: Boehringer Ingelheim GmbH - Break up of Revenue by Geographic Segment (%), 2014
LIST OF TABLES:
Table 3-1: Classification of Bulk Drugs
Table 5-1: Blockbuster Drugs Going Off Patent (2014-2015)
Table 8-1: BASF SE - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-2: Kyowa Hakko Kirin - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-3: Teva Pharmaceutical Industries Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-4: Lonza - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-5: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-6: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-7: Pfizer - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-8: Divis Laboratories Limited - Revenues (Billion US$), 2013 & 2014
Table 8-9: Royal DSM - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-10: Boehringer Ingelheim GmbH - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 3-1: Classification of Bulk Drugs
Table 5-1: Blockbuster Drugs Going Off Patent (2014-2015)
Table 8-1: BASF SE - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-2: Kyowa Hakko Kirin - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-3: Teva Pharmaceutical Industries Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-4: Lonza - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-5: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-6: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-7: Pfizer - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-8: Divis Laboratories Limited - Revenues (Billion US$), 2013 & 2014
Table 8-9: Royal DSM - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 8-10: Boehringer Ingelheim GmbH - Revenues by Business Segment (Billion US$), 2013 & 2014
